Benitec Biopharma Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

Revenue (Tables)

3 Months Ended

Sep. 30, 2020


	Three Months Ended
Revenues from customers	September 30,		September 30,
	2020		2019
Licensing revenue	$	55	$	—
Royalty revenue		—		29
Service revenue*		—		4

Total	$	55	$	33

* On July 9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. The agreement granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company’s product

BB-301,

which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company’s intellectual property related to

BB-301

and the transfer of the right to use the intellectual property of the Company’s

BB-301

license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June 6, 2019, we announced the termination of the agreement with Axovant. The termination of the agreement was effective as of September 3, 2019. The termination discharges all future performance obligations at termination date under the contract.

Summary of disaggregation of revenue


Disaggregated revenue (US$’000)	Three Months Ended September 30, 2020
	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	—	$	—
Services transferred over time		55		—		—		55

Total	$	55	$	—	$	—		55


Disaggregated revenue (US$’000)	Three Months Ended September 30, 2019
	Licensing		Royalties		Development activities		Total
Services transferred at a point in time	$	—	$	—	$	4	$	4
Services transferred over time		—		29		—		29

Total	$	—	$	29	$	4	$	33